Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by جي اي هيلثكير ايه اسfiledCriticalجي اي هيلثكير ايه اس
Priority to JO19911682ApriorityCriticalpatent/JO1682B1/en
Application grantedgrantedCritical
Publication of JO1682B1publicationCriticalpatent/JO1682B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals
(AREA)
Abstract
The physiological acceptability of contrast media, especially media for use in angiography, may be enhanced by inclusion of sub-plasma levels of sodium and calcium and, optionally , potassium and or magnesium for example 30 mm Na, 0.15 mM Ca .09 mM K and 0.1 Mm Mg
JO19911682A1991-08-251991-08-25Contrast Media
JO1682B1
(en)
Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease